Global Night Blindness Treatment Market is segmented By Treatment Type (Medication, Gene Therapy, Others) By Age Group (Pediatric, Adult) By Diagnosis (Blood tests, Color vision testing, Electroretinogram (ERG), Others) By Sales Channel (Distribution Channel, End User) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The Global Night Blindness Treatment Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2031, growing with a CAGR of YY% during the forecast period 2024-2031.
Night blindness can be caused by many disease processes, both inherited and acquired. Differentials that may cause blurred vision, and that are made worse by low light levels (e.g., cataracts, myopia, glaucoma) should be distinguished from true night blindness. The inability of the eyes to adjust to dim lighting conditions is known as night blindness. Although issues with the rod cells are the most frequent cause of night blindness, there are numerous additional causes as well.
The underlying cause determines the exact procedure for treatment for night blindness. The ageing of the retina's rods is brought on by a number of diseases. Nyctalopia is another name for disease. Eye pain, nausea, blurred vision, halos, light sensitivity, distance vision problem, and headaches are all symptoms of this diseases.
Market Scope
|
Metrics |
Details |
|
CAGR |
YY% |
|
Size Available for Years |
2023-2031 |
|
Forecast Period |
2024-2031 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
Treatment Type, Age Group, Diagnosis, Sales Channel |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details of the report - Request for sample
Market Dynamics: Drivers and Restraints
The rising prevalence of myopia and vitamin A deficiency
The rise of myopia and vitamin A deficiency are two conditions that are becoming more common, and this development will be a key factor in the market's advancement. For instance, The International Myopia Institute reported that the prevalence of myopia is rising globally and is expected to impact 50% of the world's population by 2050, primarily as a result of lifestyle factors.
The risk of sight-threatening disorders from glaucoma, cataract, and retinal detachment has also been linked to myopia. Additionally, WHO estimates that every year, between 250,000 and 500,000 children who are vitamin A deficient become blind, and half of them pass away within a year after losing their sight. Vitamin A deficiency is the largest preventable cause of childhood blindness and is related with considerable morbidity and mortality from common childhood illnesses.
The rising cost of healthcare is also a major factor affecting the market's growth rate for treatments for night blindness. The market for night blindness treatments will grow as a result of rising awareness-raising efforts by private as well as public organisations and increasing government support, in addition to developments in medical technology.
Market Dynamics: Restraint
The effectiveness of therapies can be hampered by a number of restraints on the management of night blindness. For instance, the cost of treating night blindness, particularly through surgeries and other specialised interventions, might make it difficult for those without sufficient financial means or health insurance to get the essential care.
Additionally, an immediate diagnosis is essential for managing and treating the condition effectively. Lack of extensive research and development in some areas of ophthalmology, particularly for rare or genetic causes of night blindness, can also limit the availability of advanced treatment options. Delay in identifying the underlying cause can also restrict treatment options and reduce the effectiveness of interventions.
Segment Analysis
The global night blindness treatment marketis segmented based on treatment type, age group, diagnosis, sales channel and region.
The gene therapy segment from the type segment accounted for approximately 40.7% of night blindness treatment share
A promising approach for treating a variety of genetic diseases, such as night blindness caused on by particular genetic abnormalities, is gene therapy. Nyctalopia, often known as night blindness, is frequently linked to gene variations that are crucial for the operation of retinal cells, particularly rod cells, which are responsible for seeing in low light. Researchers create a therapeutic gene that can either enhance the function of the mutant gene or replace the defective gene (gene replacement therapy). This gene is often created to improve the function of photoreceptor cells in the retina to treat night blindness.
For instance, in March 2021, according to Elsevier Inc, a study demonstrates that gene therapy can significantly improve night vision in adult mice with CSNB. Similar to this, some types of CSNB can be cured by using a special type of gene therapy that targets the nerve cells in the retina. While there is presently no treatment for CSNB, recent developments in gene therapy provide opportunity. Adaptations to enhance general quality of life and night vision are frequently necessary for managing this disease.
Geographical Analysis
North America accounted for approximately 36.4% of the market share in 2022
Due to the existence of significant key players, high disposable income, and well-established healthcare infrastructure in North America, this region dominates the market for night blindness treatments. Additionally, the prevalence of diabetes, glaucoma, and cataract will rise, along with increased attempts by governmental and commercial organisations to raise awareness. These factors will lead to an expansion of the night blindness treatment market in the region.
For instance, according to Diabetes Research Institute Foundation, around 37.3 million people, or 11.3% of the U.S. population, have diabetes. An estimated 29 million people – had diagnosed diabetes. Approximately 8.5 million people have diabetes but have not yet been diagnosed.
Additionally, according to BrightFocus Foundation 2023, more than 3 million Americans are living with glaucoma, 2.7 million of whom (aged 40 and older) are affected by its most common form, open-angle glaucoma.Thus above factors accelerates the region growth.
COVID-19 Impact Analysis
Many non-emergency medical services, such as some eye care procedures and elective operations, were postponed or cancelled during the peak of the epidemic in order to prioritize resources for COVID-19 patients. Treatments for night blindness may not have been as readily available because of this complication. Hospitals and healthcare facilities may need to give COVID-19 patients priority, which could cause delays for less urgent treatments, such as some ophthalmology-related procedures.
The scheduling and accessibility of operations linked to night blindness may be impacted by this reprioritization. The pandemic's economic effects, which include job losses and decreased income for many people, may make it more difficult for them to pay for healthcare services, including treatments for night blindness. Medical operations that are not absolutely necessary may be postponed or avoided due to financial restrictions.
Competitive Landscape
The major global players in the market include Nestle, NOWfoods Inc, Kirkland Signature, Life Extension, Garden of Life, Nidek, Inc, Alcon Laboratories, Inc, Carl Zeiss, Inc, VISX, Inc, Wavelight AG and among others.
Key Developments
- On July 21, 2022, by increasing its global formulation capabilities at its Verbund plant in Ludwigshafen, BASF is enhancing its market position in the vitamin A market. The innovative facility, which is fully integrated into vitamin production at the location, will support and increase the manufacture of high-quality vitamin A powder products for the animal nutrition industry.
- On August 07, 2023, HuidaGene, in preclinical research, its gene therapy candidate exceeded FDA-approved Luxturna. One-time gene replacement therapy called HG004 by China-based HuidaGene, which was granted orphan drug status in March 2023, is designed to treat people with inherited retinal diseases (IRDs) brought on by mutations in the RPE65 gene.
Why Purchase the Report?
- To visualize the global night blindness treatment market segmentation based on treatment type, age group, diagnosis, sales channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of night blindness treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global night blindness treatment market report would provide approximately 69 tables, 66 figures and 187 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
